Navigation Links
AMDL to Present its China Success Story at Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/22/2007

TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that its management will present on November 7, 2007, at the prestigious 9th Annual Healthcare Conference sponsored by the full-service investment bank, Rodman & Renshaw, and its life science division, Acumen BioFin(TM). The presentation will be at 2:40 PM in the Kennedy I Room (4th floor).

"The Rodman & Renshaw conference, which annually presents more than 350 companies to institutional investors, venture capitalists, and sophisticated private investors, is a major opportunity for AMDL to tell the story of its pharmaceutical successes in China," said Gary Dreher, CEO. Companies at the conference specialize in cardiovascular diseases, drug delivery, gene therapy and oncology, among other areas of investigation.

The conference is November 5 - 7 at the New York Palace Hotel, 450 Madison Avenue, New York. Information about the conference is available at Conference Schedule: http://www.rodmanandrenshaw.com/us07conference under "Program."

About JPI: Jade Pharmaceutical has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com .

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
(Date:1/23/2017)... 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... New Zealand based Phase 1 trial ... remarkable results in reducing inflamed protein biomarkers in patients ... is believed that this is the first time in ... can be made between epigenetic regulation and its potential ...
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... to bring to market a pioneering medical device for the treatment of Age-Related ... engagement contract with Emergo, a global regulatory consultancy that helps companies like ours ...
Breaking Biology Technology:
(Date:1/12/2017)... Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... technologies, today announced that it has signed agreements with ... and the Middle East for ... marks the first wave of international distribution agreements for ... blood samples. The initial partners will introduce ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, Inc., ... in healthy volunteers of a novel calcium release-activated ... acute pancreatitis. Acute pancreatitis, sudden ... mild disorder, but can be very serious.  In severe ... sepsis, where extended hospital stays, time in the ...
(Date:1/3/2017)... 3, 2017 Onitor, provider of digital health ... Track, an innovative biometric data-driven program designed to aid ... at the 2017 Consumer Electronics Show (CES) in ... the U.S., the World Health Organization (WHO), have identified ... adults who are overweight or obese. WHO also states ...
Breaking Biology News(10 mins):